- Home
- RLYB
RLYB
Rallybio Corporation
as 07-26-2024 4:00pm EST
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 53.5M | IPO Year: | 2021 |
| Target Price: | $8.90 | AVG Volume (30 days): | 306.3K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $6.33 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Rallybio Corporation News
RLYB Breaking Stock News: Dive into RLYB Ticker-Specific Updates for Smart Investing
Business Wire
18 days ago
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
Business Wire
a month ago
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
PR Newswire
2 months ago
NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
Business Wire
2 months ago
Form 8.3 - International Distribution Services plc
Business Wire
2 months ago
Form 8.3 - Darktrace plc
Reuters
2 months ago
US Supreme Court rejects Kroger challenge to Grubhub trademark win
Investor's Business Daily
2 months ago
Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect
GlobeNewswire
2 months ago
Middlefield Canadian Income PCC: Net Asset Value(s)
Compare RLYB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLYB Rallybio Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.